echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The prevention and control of bivalent HPV vaccine reaches 84.5%. It is recommended to vaccinate as soon as possible

    The prevention and control of bivalent HPV vaccine reaches 84.5%. It is recommended to vaccinate as soon as possible

    • Last Update: 2021-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Expert: The prevention and control rate of bivalent HPV vaccine reaches 84.


    China News Service, Guangzhou, July 18 (Cai Minjie and He Yuhang) The current cervical cancer vaccines include domestically produced two-valent, imported two-valent, four-valent, and nine-valent vaccines
    .


    Wang Ming, chief expert of the Guangzhou Preventive Medicine Association, participated in the "Cervical Cancer and Hepatitis E Disease Prevention and Control Strategy Symposium" held in Guangzhou on the 18th, said that HPV (papilloma virus) 16 and HPV 18 are the two types with the highest risk.


    Human papillomavirus is abbreviated as HPV, which is the main cause of cervical cancer
    .


    Cervical cancer is the fourth leading malignant tumor for women in the world and the largest gynecological malignant tumor in the Mainland


    In 2018, the World Health Organization called for the global elimination of cervical cancer.
    The vaccination coverage rate for girls between 9 and 14 years old needs to reach 90%.
    However, the current vaccination rate for girls between 9 and 14 years old in the Mainland is less than 0.
    05%.
    There is a long way to go to eliminate cervical cancer
    .

    Cervical cancer is preventable and controllable and requires early vaccination and early protection
    .


    Currently, China is the only country in the world that has four HPV vaccines on the market


    Studies have shown that more than 84.
    5% of cervical cancers are infected by HPV16 and HPV18 viruses.
    The domestically marketed bivalent and quadrivalent vaccines can protect against these two most dangerous precancerous lesions
    .


    "Bivalent vaccines mainly prevent two high-risk subtypes, 16 and 18, and can be vaccinated for people aged 9 to 45.


    In December 2019, the National Medical Products Administration approved Xiamen Wantai Biotech's bivalent human papillomavirus vaccine to be marketed
    .


    This is the first domestically approved HPV vaccine for women between 9 and 45 years old


    Wang Ming said that cervical cancer is currently the only malignant tumor with a clear etiology, preventable and controllable.
    In developed countries, through continuous improvement of screening management and universal inoculation of cervical cancer vaccines, its morbidity and mortality have decreased significantly.

    .


    (Finish)

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.